Strides Pharma Sciences News Today

Indian law firm J. Sagar Associates has continued its aggressive expansion with the addition of real estate partner Brijita Prakash and corporate partner Santosh Vijay in Bengaluru, making it six partner hires in just over a month for the firm.

13.75 lakh shares of Strides Pharma Sciences changed hands, following which, the stock price sank over 1.5 percent

Sharekhan recommended Hold rating on Strides Pharma Sciences with a target price of Rs 491 in its research report dated August 02, 2023.

Sharekhan is bullish on Strides Pharma Sciences Ltd has recommended buy rating on the stock with a target price of Rs 450 in its research report dated June 01, 2023.

Read more about Strides, TLC partner to launch liposomal amphotericin B in India on Business Standard. The drug maker on Thursday announced that announced that the Central Drugs Standard Control Organization (CDSCO) of India has approved TLCs New Drug Application (NDA) of Amphotericin B Liposome for injection 50 mg.

The company on Thursday, announced that the CDSCO in India has approved TLC’s New Drug Application

Strides Pharma to pursue portfolio maximisation in regulated markets February 10, 2021 R Ananthanarayanan, Managing Director & CEO, Strides Pharma Sciences× To develop products across multiple therapeutics segments Strides Pharma Science Limited plans to pursue portfolio maximisation strategy across the regulated markets to unlock value. It is also exploring to develop a wide range of products across multiple therapeutics segments. “Further to the Stelis demerger, Strides will keep open the...